Sign in
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Journal article   Open access  Peer reviewed

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Nancy L Bartlett, Robert Chen, Michelle A Fanale, Pauline Brice, Ajay Gopal, Scott E Smith, Ranjana Advani, Jeffrey V Matous, Radhakrishnan Ramchandren, Joseph D Rosenblatt, …
Journal of hematology and oncology, Vol.7(1), pp.24-24
2014-03-19
PMCID: PMC3994656
PMID: 24642247

Abstract

Retreatment Relapse Brentuximab vedotin Research Hodgkin lymphoma Systemic anaplastic large cell lymphoma
url
https://doi.org/10.1186/1756-8722-7-24View
Published (Version of record) Open

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.130 Lymphomas
1.130.132 Lymphoma
Web Of Science research areas
Hematology
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details